HUTCHMED (China) Limited (AIM: HCM)
London
· Delayed Price · Currency is GBP · Price in GBX
279.88
-4.12 (-1.45%)
Nov 21, 2024, 10:28 AM GMT+1
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $305.68M USD in the half year ending June 30, 2024, with 51.29% growth. This brings the company's revenue in the last twelve months to $610.81M, down -19.34% year-over-year. In the year 2023, HUTCHMED (China) had annual revenue of $838.00M with 96.52% growth.
Revenue (ttm)
$610.81M
Revenue Growth
-19.34%
P/S Ratio
4.91
Revenue / Employee
$307.25K
Employees
1,988
Market Cap
2.38B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHUTCHMED (China) News
- 3 days ago - HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - GlobeNewsWire
- 17 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress - GlobeNewsWire
- 23 days ago - HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - GlobeNewsWire
- 7 weeks ago - HUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2 - GuruFocus
- 2 months ago - HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - GlobeNewsWire
- 2 months ago - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Benzinga
- 2 months ago - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer - GlobeNewsWire